Literature DB >> 21238902

Adherence to antihypertensive therapy affects Ambulatory Arterial Stiffness Index.

Andrea Berni1, Elisa Ciani, Ilaria Cecioni, Loredana Poggesi, Rosanna Abbate, Maria Boddi.   

Abstract

BACKGROUND: A major contributor to poor blood pressure (BP) control is nonadherence to therapy, which remains poorly recognized by physicians. The prevention of hypertension-induced changes in arterial wall, namely increased arterial stiffness and peripheral vascular resistance, is a reasoned adequate end-point of hypertension treatment. Indirect measurement of these arterial factors can be derived from the analysis of 24-hour Ambulatory BP Monitoring (24 h-ABPM). This pilot study evaluated the association between antihypertensive therapy adherence and 24 h-ABPM-derived parameters in hypertensive patients.
METHODS: We studied 42 hypertensive patients (70±10 years) in chronic antihypertensive therapy. Patients were divided according to the Morisky Medication Adherence Scale (MMAS) in Low-Adher (MMAS <6) and High-Adher (MMAS 6-8) groups. The Ambulatory Arterial Stiffness Index (AASI) and its symmetric calculation (Sym_AASI) were derived from 24 h-ABPM. A bivariate logistic regression analysis was performed to evaluate the predictive value of MMAS for increased AASIs (i.e. above the median).
RESULTS: Low-Adher group (n=17) showed higher AASIs compared to High-Adher group (n=25). The two groups were similar in terms of BP burden at the 24 h-ABPM. AASIs were inversely related to MMAS. MMAS resulted a predictor for both increased AASI (O.R. 0.49, 95% CI 0.31-0.76, P<0.01) and increased Sym_AASI (O.R. 0.67, 95% CI 0.47-0.95, P=0.026). After adjustment for PP, age and nocturnal diastolic BP reduction, MMAS persisted as an inverse predictor only of increased AASI. MMAS was also related to the diastolic vs systolic BP correlation coefficient r.
CONCLUSIONS: Low adherence to antihypertensive therapy seems to be associated with increased standard AASI. In this setting, AASI could represent an additional information derived from the 24 h-ABPM in hypertensive patient evaluation.
Copyright © 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21238902     DOI: 10.1016/j.ejim.2010.07.015

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

1.  The clinical utility of the Medication Adherence Questionnaire (MAQ) in an alcohol pharmacotherapy trial.

Authors:  A Zweben; M E Piepmeier; L Fucito; S S O'Malley
Journal:  J Subst Abuse Treat       Date:  2017-04-04

Review 2.  A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model.

Authors:  Suliman A AlGhurair; Christine A Hughes; Scot H Simpson; Lisa M Guirguis
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-20       Impact factor: 3.738

3.  [Drug compliance and its factors in a group of hypertensive Congolese].

Authors:  Méo Stéphane Ikama; Bernice Mesmer Nsitou; Mpouoni Loumouamou; Gisèle Kimbally-Kaky; Jean Louis Nkoua
Journal:  Pan Afr Med J       Date:  2013-08-06

Review 4.  Nonadherence to antihypertensive drugs: A systematic review and meta-analysis.

Authors:  Tadesse Melaku Abegaz; Abdulla Shehab; Eyob Alemayehu Gebreyohannes; Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

5.  Predictors of poor medication adherence of older people with hypertension.

Authors:  Jingjing Wan; Yinyin Wu; Yuan Ma; Xiubin Tao; Anshi Wang
Journal:  Nurs Open       Date:  2022-01-30

6.  Magnitude and determinants of uncontrolled blood pressure among hypertensive patients in Ethiopia: hospital-based observational study.

Authors:  Tadesse M Abegaz; Ousman A Abdela; Akshaya S Bhagavathula; Fitsum S Teni
Journal:  Pharm Pract (Granada)       Date:  2018-06-22

7.  Psychometric properties of the scale for non-adherence to antiretroviral medication (NAME) among HIV-infected patients.

Authors:  Zahra Hosseini; Hassan Eftkhar; Teamur Aghamolaei; Abbas Ebadi; Saharnaz Nedjat; Ladan Abbasian; Minasadat Hashemi Parast
Journal:  Arch Public Health       Date:  2019-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.